Latest Us Army News

Li-S Energy says its Geelong lithium-sulfur production line is complete and has delivered 10Ah Power Cells to the US Army for testing. The company is targeting its first commercial battery sale in 2027, while holding A$15.6 million in cash and investments and A$9.3 million in secured grants yet to be received.

Li-S Energy has inked a strategic collaboration with Australian defence firm EPE, unlocking pathways to international defence markets for its ultra-lightweight lithium sulfur batteries.

Island Pharmaceuticals has obtained regulatory rights to reference critical Marburg-Angola virus natural history data, clearing a significant FDA hurdle for its antiviral Galidesivir. This milestone accelerates the path toward pivotal animal studies and potential FDA approval under the Animal Rule.

IperionX has landed a second U.S. Army task order worth US$11.5 million to expand its industrial-scale titanium manufacturing capacity in Virginia, advancing its integrated powder-to-part platform for defense applications.

Li-S Energy has shipped its first lithium-sulfur battery cells to the US Army DEVCOM C5ISR Center, marking a key milestone in its commercialisation and opening a pathway into US defence procurement.

Environmental Clean Technologies has secured A$10.6 million in a placement to fast-track commercialisation of its Flash Joule Heating platform and MXene manufacturing, backed by a strategic acquisition and feedstock supply.

Vitrafy Life Sciences reported an 80% revenue surge and halved its net loss, buoyed by US military validation and major blood network partnerships. A $32 million capital raise fuels its US commercial expansion and manufacturing scale-up.

Island Pharmaceuticals has marked a major step forward in its antiviral program with the start of GMP manufacturing for Galidesivir, expanded USAMRIID collaboration, and FDA orphan drug designation. Regulatory approvals for compassionate use in Uganda’s Ebola outbreak and a new dose optimisation study with Texas Biomed further de-risk the pathway to approval.

Ioneer Ltd continues to build momentum on its Rhyolite Ridge lithium-boron project, signing strategic MOUs with Korean partners and navigating a legal appeal while preparing for construction.

Vitrafy Life Sciences reported a breakthrough 94.4% post-thaw platelet recovery in US Army Phase II testing, secured major US blood network partnerships, and raised $32 million to accelerate US expansion and device manufacturing.

Electro Optic Systems (ASX:EOS) posted a 284% surge in first-half 2026 revenue to $169 million, driven by robust defence contracts and regional tensions. Its order book hit a historic $846 million, prompting an upgrade to full-year guidance and signalling strong momentum in counter-drone and laser weapon systems.

Elsight Limited (ASX:ELS) has shattered its revenue records in H1 2026, delivering a nearly fourfold increase over the prior year alongside expanding US defence contracts and new product launches.